sglt2 inhibitors vs glp 1 agonists Cardiorenal Protection: Potential of and GLP-1 Receptor in the Treatment of Type 2 Diabetes | Diabetes Therapy Disparities in SGLT2 Inhibitor or
Description
Combining GLP 1 medications with these glucose lowering agents substantially increases hypoglycemia risk
Tirzepatide (SUMO trials) demonstrated superior efficacy: 22.5% at 10 mg, 24.2% at 15 mg over 72 weeks
There are oral versions of these medications, but they are not yet approved for weight loss
Likewise, you might be able to get your GLP-1 RA approved based on one of your conditions rather than another
A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase 2 clinical trial
doi: 10.2337/db17-1212
